New Member
Posted 14 May 2012 - 06:43 AM
''Some bad bosutinib is going around. Scientists who have purchased the compound may have actually received an isomer rather than the genuine molecule''
Extract of Bosutinib Buyer Beware from Chemical & Engineering News
More information about Bosutinib
Advanced Member
Posted 14 May 2012 - 09:18 AM
People need to be very clear about what is happening here. The articles I have read specifically state that the patient supply is fine. The issue has to do with samples of the compound given to researchers through third party suppliers. It is a big deal and it something to be aware of, but as of now Pfizer states that no patients have been given a compromised drug. Unfortunately a number of research efforts may be hampered by this. So the take away at this point is if you are a patient taking bosutinib, everything is fine. If you are a researcher studying bosutinib, you may be screwed.
New Member
Posted 14 May 2012 - 07:50 PM
Lucky is indeed correct. Only the research supply (meaning it is not pharmaceutical grade, ie, not to be taken by patients) is in question. My company gets their supply directly from the Pharma company. The problem occurred when other suppliers began to offer it by using a different synthetic method (recipe) to make it, rather than get supply from Pharma company. They just got it wrong.
Only researchers should be affected, which means they may need to redo some experiments, or rethink some decisions. Some may need to make corrections to published papers, don't know if it was caught early enough.
Makes me wonder if Pharma company involved will serve a cease and desist order on companies selling wrong material. They don't want a lot of publications about pseudo bosutinib being mistaken for the real deal.
Upshot is patient supply is safe.
Traci
0 members, 1 guests, 0 anonymous users
